Log in
Infectious and parasitic diseases

Variant Creutzfeldt–Jakob disease

Variant Creutzfeldt-Jakob disease (vCJD) is a fatal, transmissible spongiform encephalopathy caused by prion infection acquired primarily from consuming beef contaminated with the bovine spongiform encephalopathy (BSE) agent. It classically affects younger patients than sporadic CJD and presents first with psychiatric symptoms before progressing to ataxia and dementia. The single most testable fact: the pulvinar sign (bilateral posterior thalamic hyperintensity) on MRI is highly specific for vCJD.

Practice questionsHigh-yield facts
ICD-10A81.0 (vCJD), F02.1 (dementia in CJD)
Typical patientYoung adult, UK-linked beef exposure, psychiatric prodrome
Key findingPulvinar sign on brain MRI; psychiatric onset
First-line treatmentSupportive care only; no disease-modifying therapy
6 min readFor medical studentsUpdated 2026-10-14

Definition and epidemiology

Variant Creutzfeldt-Jakob disease is a human prion disease caused by infection with the same prion strain responsible for bovine spongiform encephalopathy (BSE) in cattle. It belongs to the family of transmissible spongiform encephalopathies, which also includes sporadic CJD, familial CJD, kuru, and Gerstmann-Straussler-Scheinker syndrome.

vCJD emerged in the United Kingdom in the mid-1990s following a BSE epidemic in cattle during the 1980s, linked to contaminated meat-and-bone meal feed. Most cases have occurred in the UK, with smaller numbers in France and a handful of other countries, almost always in people with a history of residence in or travel to the UK during the BSE outbreak years.

  • Case numbers have dropped sharply since the early 2000s due to BSE control measures and dietary changes.
  • Median age at onset is substantially younger than sporadic CJD (twenties, versus sixties to seventies for sporadic disease).
  • A small number of cases have also resulted from secondary transmission via blood transfusion from asymptomatic infected donors.
  • The large majority of confirmed cases are homozygous for methionine at codon 129 of the PRNP gene (MM genotype); a confirmed case has also occurred in a methionine/valine (MV) heterozygote, so other genotypes are not immune, and concern remains about possible longer incubation periods in non-MM genotypes.
High-yield for exams
  • vCJD is caused by the same prion strain as bovine BSE, acquired mainly through contaminated beef.
  • Younger patients than sporadic CJD; median onset in the 20s to 30s.
  • Early psychiatric symptoms (depression, anxiety, psychosis) precede neurological decline.
  • Painful sensory dysesthesias are a distinctive early feature.
  • MRI pulvinar sign (bilateral posterior thalamic hyperintensity) is highly suggestive of vCJD.
  • Florid plaques on neuropathology and early lymphoreticular (tonsil) prion deposition distinguish vCJD from sporadic CJD.
  • The vast majority of confirmed cases are PRNP codon 129 methionine homozygous (MM), but vCJD has also been confirmed in an MV heterozygote.
  • Standard CSF RT-QuIC is typically negative in vCJD, unlike in sporadic CJD where it is highly sensitive and specific.
  • No curative or disease-modifying treatment exists; management is supportive and palliative.

Etiology and risk factors

vCJD is caused by misfolded prion protein (PrP-sc), an abnormal conformational isoform of the normal cellular prion protein (PrP-c). The disease is not caused by a conventional pathogen (virus, bacterium, fungus) but by a self-propagating protein that induces conformational change in normal PrP.

Routes of acquisition

  • Dietary exposure: ingestion of BSE-contaminated beef products, particularly those containing nervous system tissue (brain, spinal cord), during the UK BSE epidemic.
  • Iatrogenic/secondary transmission: blood transfusion, and theoretically other blood products or contaminated surgical instruments, though documented cases are mainly transfusion-related.
  • Genetic susceptibility: PRNP codon 129 methionine homozygosity (MM) is a major susceptibility factor and accounts for the vast majority of cases, but variant CJD has also been confirmed in a methionine/valine (MV) heterozygote, showing that other codon 129 genotypes are also susceptible.

There is no evidence of person-to-person transmission through casual contact, and no evidence it is transmitted sexually or via standard respiratory routes.

Pathophysiology

The pathogenic mechanism centers on prion protein misfolding and templated propagation.

  • Normal PrP-c is a cell-surface glycoprotein that is alpha-helix rich.
  • The abnormal isoform PrP-sc is beta-sheet rich, protease-resistant, and acts as a template that converts normal PrP-c into more PrP-sc.
  • This conversion is self-amplifying and does not require nucleic acid, distinguishing prions from viruses.
  • Accumulated PrP-sc aggregates in neural tissue, causing neuronal loss, spongiform (vacuolar) change, and astrocytic gliosis.

A distinguishing pathological feature of vCJD compared with sporadic CJD is the presence of abundant florid plaques, amyloid-core plaques surrounded by a halo of spongiform vacuolation, most prominent in the cerebellum and cerebrum. Importantly, prion accumulation in vCJD is also found in lymphoreticular tissue (tonsil, appendix, spleen, lymph nodes) early in the disease course, which does not occur in sporadic CJD and underlies the diagnostic utility of tonsillar biopsy.

Clinical features

vCJD typically evolves over months, somewhat more slowly than sporadic CJD, which progresses over weeks.

Early (psychiatric) phase

  • Depression, anxiety, apathy, or withdrawal
  • Delusions, hallucinations
  • Insomnia
  • Sensory symptoms, including persistent painful dysesthesias or paresthesias in the limbs or face (a relatively distinctive early feature)

Later (neurological) phase

  • Cerebellar ataxia
  • Progressive cognitive decline and dementia
  • Myoclonus and chorea
  • Pyramidal and extrapyramidal signs
  • Akinetic mutism in the terminal stage

The disease is uniformly progressive and fatal, with a mean survival from symptom onset of around 12 to 14 months, longer than the typical few-month course of sporadic CJD.

Diagnosis

Diagnosis is largely clinical, supported by imaging, electrophysiology, and tissue-based tests. Definitive diagnosis requires neuropathological confirmation, but probable diagnosis is possible in life using validated criteria combining clinical features with investigations.

Key investigations

TestFinding in vCJD
MRI brainPulvinar sign (bilateral thalamic posterior hyperintensity), hockey-stick sign
EEGUsually lacks the periodic sharp-wave complexes typical of sporadic CJD
CSF 14-3-3 proteinLess consistently positive than in sporadic CJD
CSF RT-QuICTypically negative with standard assays; a negative result helps distinguish vCJD from sporadic CJD, where it is highly sensitive and specific
Tonsil biopsyDetects PrP-sc in lymphoid tissue; useful because of early lymphoreticular involvement
Brain biopsy/autopsyFlorid plaques, spongiform change; gold standard
  • MRI pulvinar sign is the most clinically useful supportive test and is seen in the large majority of confirmed cases.
  • Genetic testing for PRNP mutations helps exclude familial prion disease.
  • Routine CSF studies are otherwise nonspecific (mild protein elevation, no pleocytosis).

Differential diagnosis

  • Sporadic CJD: older patients, faster course, periodic sharp waves on EEG, positive CSF 14-3-3 and RT-QuIC more often, no lymphoreticular prion deposition.
  • Alzheimer disease and other dementias: much slower progression, lacks the psychiatric prodrome and ataxia pattern of vCJD.
  • Autoimmune/paraneoplastic encephalitis (e.g., anti-NMDA receptor encephalitis): can mimic rapid psychiatric and neurological decline but typically has distinct autoantibodies and may respond to immunotherapy.
  • Major depressive disorder with psychotic features: can resemble the early psychiatric phase but lacks progressive neurological signs.
  • Wilson disease: younger patient with movement disorder and psychiatric symptoms, but has characteristic copper studies and Kayser-Fleischer rings.
  • Hashimoto encephalopathy: steroid-responsive, associated with thyroid autoantibodies.
  • Vitamin deficiency states (B12, thiamine): reversible causes of cognitive and neurological decline that must be excluded.

Management

There is no cure and no disease-modifying or antiprion therapy proven effective in clinical trials; management is entirely supportive and multidisciplinary.

Supportive care principles

  • Symptom control for myoclonus, agitation, and psychiatric symptoms using standard psychotropic and antiepileptic agents as needed.
  • Management of pain, particularly the dysesthetic limb pain common in vCJD.
  • Nutritional support, including consideration of enteral feeding as swallowing deteriorates.
  • Palliative and end-of-life care planning, given the uniformly fatal and progressive course.
  • Infection control precautions for healthcare workers and during surgical/invasive procedures, since standard sterilization does not reliably inactivate prions; specific decontamination protocols and instrument quarantine/disposal are used for suspected or confirmed cases.
  • Public health measures: blood and organ donation deferral for at-risk individuals, and notification to relevant national surveillance units (e.g., national CJD surveillance programs), as vCJD is a reportable condition in most jurisdictions.

Several agents (e.g., quinacrine, pentosan polysulfate, flupirtine, doxycycline) have been studied in prion disease but none has demonstrated a convincing survival or functional benefit in controlled trials, and none is recommended as standard therapy by current guidelines.

Complications and prognosis

vCJD is invariably fatal. Death typically occurs within about 1 to 2 years of symptom onset, with akinetic mutism, immobility, and inability to swallow preceding death.

  • Complications relate largely to progressive immobility and dementia: aspiration pneumonia, pressure ulcers, venous thromboembolism, and malnutrition.
  • There is no spontaneous recovery; the disease course is relentlessly progressive.
  • Because of the risk of secondary transmission (blood transfusion, instrument contamination), confirmed or probable cases trigger public health investigation and contact tracing of blood/tissue recipients where relevant.
Mnemonic

Think "PRIONS" for vCJD: Psychiatric onset, Rapidly progressive (over months), Imaging shows pulvinar sign, Oral transmission (BSE beef), No cure, Spongiform pathology with florid plaques.

Practice questions

1. A 24-year-old woman from the United Kingdom presents with a 6-month history of depression, anxiety, and new-onset painful tingling sensations in her legs. Her family reports she has become increasingly clumsy and forgetful over the past 2 months. Neurologic exam shows ataxia and mild cognitive impairment. MRI brain shows bilateral hyperintensity in the posterior thalami. Which of the following is the most likely diagnosis?

Answer: B. The combination of young age, UK residence, early psychiatric prodrome, painful dysesthesias, ataxia, and the MRI pulvinar sign (bilateral posterior thalamic hyperintensity) is classic for variant CJD. Sporadic CJD typically occurs in older patients with a faster course and periodic sharp-wave EEG complexes rather than a pulvinar sign.

2. A pathologist examining postmortem brain tissue from a patient who died of a rapidly progressive dementia notes spongiform change, neuronal loss, and amyloid-core plaques surrounded by a halo of vacuolation, most prominent in the cerebellum. These plaques are most characteristic of which condition?

Answer: C. Florid plaques, amyloid cores surrounded by a halo of spongiform vacuolation and concentrated in the cerebellum, are a pathological hallmark of variant CJD, distinguishing it from sporadic CJD, which does not typically show this plaque pattern. Alzheimer disease shows neuritic plaques and neurofibrillary tangles, not spongiform change.

3. A 30-year-old man is being evaluated for suspected variant CJD. His physician wants to use a test that exploits the fact that this prion disease, unlike sporadic CJD, shows early involvement of lymphoreticular tissue. Which tissue would be most useful for this diagnostic biopsy?

Answer: C. Variant CJD characteristically deposits abnormal prion protein in lymphoreticular tissue, including tonsils, spleen, and lymph nodes, early in the disease course, unlike sporadic CJD. Tonsillar biopsy can therefore detect PrP-sc and support the diagnosis in a living patient, which is not useful in sporadic CJD.

Frequently asked questions

What causes variant Creutzfeldt-Jakob disease?

Variant CJD is caused by infection with an abnormal prion protein, the same agent responsible for bovine spongiform encephalopathy (BSE) in cattle. Humans acquire it mainly by eating beef products contaminated with BSE-infected nervous tissue, and rarely through blood transfusion from an infected donor. It is not caused by a virus or bacterium but by a misfolded, self-propagating protein.

What are the first symptoms of variant CJD?

The earliest symptoms are usually psychiatric rather than neurological, including depression, anxiety, social withdrawal, or psychotic symptoms such as hallucinations. Many patients also develop unusual painful sensory symptoms (dysesthesias) in the limbs or face. Ataxia, memory loss, and movement abnormalities typically follow weeks to months later.

How is variant CJD diagnosed?

Diagnosis relies on clinical features plus supportive tests, since there is no single confirmatory blood test used in life for most cases. Brain MRI showing the pulvinar sign, EEG, CSF studies (including RT-QuIC, which is typically negative in vCJD), and tonsil biopsy for lymphoid prion detection all support the diagnosis. Definitive confirmation requires neuropathological examination of brain tissue, usually at autopsy.

Is variant CJD curable?

No, variant CJD is not curable and is uniformly fatal. There is no treatment that stops or reverses prion accumulation, and care is entirely supportive, focused on symptom control and quality of life. Most patients die within one to two years of symptom onset.

Variant CJD vs sporadic CJD — what is the difference?

Variant CJD affects younger patients, progresses somewhat more slowly, and begins with psychiatric symptoms, while sporadic CJD typically affects older adults and progresses rapidly over weeks with early dementia and myoclonus. Variant CJD is linked to BSE-contaminated beef exposure, shows florid plaques and lymphoreticular prion deposition on pathology, and produces the MRI pulvinar sign with typically negative CSF RT-QuIC, features not typical of sporadic CJD.

Sporadic Creutzfeldt-Jakob diseaseKuruGerstmann-Straussler-Scheinker syndromeFatal familial insomniaBovine spongiform encephalopathyAnti-NMDA receptor encephalitisAlzheimer diseaseWilson disease

Sources and further reading

StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: A81.0

Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.